Childhood Absence Epilepsy Clinical Trial
Official title:
Functional Neuroimaging in Childhood Absence Epilepsy
Our study examines which different brain regions are involved in child absence seizures and how they are related to attention and cognition.
The fundamental mechanisms of altered brain function and impaired attention in childhood
absence epilepsy (CAE) are not known. Absence seizures consist of brief 5-10 seconds
episodes of unresponsiveness, associated with a 3-4 Hz "spike-wave" discharge on
electroencephalogram (EEG). CAE affects 10-15% of children with epilepsy. In addition to the
deficit during seizures, many children also suffer from milder attention impairment between
absence episodes, which may not be due entirely to medications. Impaired attention during
and between absence seizures has a major negative impact on patient quality of life due to
deficits in school performance, potential for injuries, and social stigma.
Recent studies suggest that impaired cognition in so-called "generalized" absence seizures
may, in fact, depend on dysfunction in specific brain networks. Our central hypothesis is:
abnormal function in focal brain regions, such as the anterior cingulate/medial prefrontal
cortex and medial thalamus, causes impaired attention both during and between seizures in
CAE. If confirmed, this may lead to innovative regional therapies targeted at improving
impaired attention in CAE. Specifically, we hope to determine which specific cortical and
sub-cortical networks are selectively involved when patients show impaired attention. Using
simultaneous EEG and functional magnetic resonance imaging (fMRI), we will determine which
brain regions are involved in absence seizures while using a continuous performance task
(CPT) to test attention vigilance in the same patients. A few neuropsychology tests will
then follow. Patients will be reimbursed $100 as well as all travel and parking expenses.
For more information, please visit www.yalecae.com
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT06153186 -
Flunarizine for Treatment Resistant Absence Epilepsy
|
Phase 2 | |
| Enrolling by invitation |
NCT05109234 -
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
|
Phase 3 | |
| Not yet recruiting |
NCT06315322 -
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
|
Phase 3 | |
| Recruiting |
NCT04666610 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
|
Phase 3 | |
| Completed |
NCT00088452 -
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
|
Phase 3 | |
| Terminated |
NCT03355300 -
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
|
Phase 2 | |
| Terminated |
NCT03336242 -
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
|
Phase 2 | |
| Completed |
NCT00361010 -
A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy
|
N/A | |
| Completed |
NCT00041951 -
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study
|
N/A | |
| Recruiting |
NCT06310772 -
Assessing Comorbidities in Epilepsy Using Eye Movement Recordings
|